Bing

SEARCH HISTORY

CHICAGO, July 31, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FIT, GILD, AAL, SKX and JBLU. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting …
Financial Content · 10 hours ago
Gilead Sciences
Drilling down, specific drugmakers grabbing the attention of Wall Street today include Merck & Co., Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and Gilead Sciences, Inc. (NASDAQ:GILD). MRK reported ... per the …
Schaeffer's Investment Research · 7/29/2015
PFE
Adami believes the stock will push higher despite the brief selling ... Karen is long BABA, BAC, C, FINL, FL, GILD, GOOG, GOOGL, JPM, KORS, M, BABA puts, she is short SPY, Her firm is long ANTM, AAPL, BAC, C …
CNBC · 1 day ago
GILD) crashed 18% as the PBM took similar action against the HCV drugs. Amgen, Inc. (NASDAQ:AMGN) meanwhile has said that it's all set to hold talks with health insurers and payers, and negotiate the pricing and …
bidnessetc.com · 1 day ago
Express Scripts
For Gilead Sciences GILD 2.82 % shareholders, the future is scarier than the present. Yet that presents biotech investors with a rare value opportunity. Gilead’s stock rose 4% after it posted strong second-quarter …
Wall Street Journal · 7/29/2015
Gilead
Twitter, Inc. (TWTR)’s monthly performance stand at 3.63% with a profit margin of -38.30% and has an analyst rating of 2.5 (Click To Expand Current Stock Data:) Yelp Inc. (YELP) of the Technology sector (Internet …
wallstreetscope.com · 7/29/2015
Gilead Sciences (NASDAQ: GILD) 3% HIGHER; reported Q2 EPS of $3.15 ... declared a quarterly cash dividend of $0.07 per share of common stock. The quarterly dividend will be paid on October 1, 2015, to …
StreetInsider · 7/29/2015
Gilead Sciences Inc. (NASDAQ:GILD) [Detail Analytic Report] share price dropped in the stock market with 2.01% and trade at $115.80 on Friday early hours session. In the recent reports the flagship drugs by the …
streetwisereport.com · 7/24/2015
Gilead Sciences Inc. (GILD) reported second quarter non-GAAP EPS of $3.15 after the bell Tuesday, which exceeded the consensus estimate of $2.71. The stock is now up 3.63 on 1.3 million shares. Gilead Sciences gapped up at the open Tuesday, but …
Realtime Business News · 7/28/2015
Tuesday's rally was yet another instance where investors proved that they want to buy stocks after every stock market sell-off ... Gilead Sciences Inc. (NASDAQ: GILD) shares were trading up 35 at $116.75 or so in early Wednesday trading after beating ...
Market Watch · 7/29/2015

Gilead Sciences

Company
Gilead Sciences is an American biotechnology company that discovers, develops and commercializes therapeutics. For many y…
Gilead Sciences is an American biotechnology company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B, hepatitis C, or influenza. In 2006, Gilead acquired two companies that were developing drugs to treat patients with pulmonary diseases. The company has fourteen commercially available products. Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2009, the company had approximately 4,000 full-time employees. The company's name and logo refer to the Balm of Gilead.
Data from: Wikipedia